patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_181810 | REC_0012601 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 8 | 66 | male | 0 | 19 | 4.1 | 6 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:00.041040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144313 | REC_0012602 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.3 | 75 | female | 1 | 71 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.1 | true | MSS | 2026-03-15T05:36:00.041429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881385 | REC_0012603 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 15.3 | 76 | female | 1 | 9 | 4.7 | 2 | entrectinib 600 mg daily | 21.2 | false | MSS | 2026-03-15T05:36:00.041817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499279 | REC_0012604 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.3 | 71 | female | 2 | 15 | 6.9 | 5 | alectinib 600 mg BID | 9.7 | false | MSS | 2026-03-15T05:36:00.044371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979276 | REC_0012605 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 11 | 12.5 | 70 | female | 0 | 19 | 4.9 | 5 | entrectinib 600 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:00.044889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121238 | REC_0012606 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10.5 | 55 | male | 1 | 13 | 6.5 | 2 | entrectinib 600 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:36:00.045270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847025 | REC_0012607 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.5 | 60 | male | 0 | 21 | 5.6 | 4 | osimertinib 80 mg daily | 8.1 | false | MSS | 2026-03-15T05:36:00.045618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360365 | REC_0012608 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 13.9 | 67 | female | 1 | 2 | 6.1 | 6 | entrectinib 600 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:36:00.045970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227836 | REC_0012609 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 11.5 | 63 | female | 0 | 13 | 5.6 | 1 | entrectinib 600 mg daily | 21.2 | false | MSI-H | 2026-03-15T05:36:00.046317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629932 | REC_0012610 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 9.2 | 65 | male | 0 | 23 | 5.3 | 6 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:00.046664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791330 | REC_0012611 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.7 | 66 | female | 1 | 16 | 6.2 | 1 | osimertinib 80 mg daily | 25 | false | MSI-H | 2026-03-15T05:36:00.047191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265138 | REC_0012612 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.7 | 70 | male | 2 | 14 | 5.1 | 4 | osimertinib 80 mg daily | 16.8 | true | MSI-H | 2026-03-15T05:36:00.047531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218358 | REC_0012613 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 12.5 | 64 | female | 0 | 5 | 6.3 | 3 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:36:00.047853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678678 | REC_0012614 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 17 | 10.2 | 66 | female | 1 | 18 | 4.9 | 0 | sotorasib 960 mg daily | 55.9 | true | MSS | 2026-03-15T05:36:00.049500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984433 | REC_0012615 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.8 | 62 | male | 1 | 25 | 5.7 | 3 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:00.050051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544549 | REC_0012616 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.6 | 73 | female | 3 | 10 | 6.3 | 7 | alectinib 600 mg BID | 10.9 | false | MSI-H | 2026-03-15T05:36:00.050465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450101 | REC_0012617 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 15.6 | 66 | male | 0 | 16 | 4.9 | 7 | alectinib 600 mg BID | 19.3 | false | MSI-H | 2026-03-15T05:36:00.050836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736661 | REC_0012618 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 17.2 | 66 | female | 1 | 12 | 5.9 | 6 | pembrolizumab 200 mg q3w | 14.7 | false | MSS | 2026-03-15T05:36:00.051220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322573 | REC_0012619 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 18.2 | 54 | female | 0 | 16 | 7.6 | 2 | entrectinib 600 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:36:00.051557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376949 | REC_0012620 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 15.8 | 61 | male | 0 | 5 | 5.3 | 0 | osimertinib 80 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:36:00.051896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464726 | REC_0012621 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 4.9 | 73 | female | 2 | 42 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.5 | false | MSS | 2026-03-15T05:36:00.052905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949683 | REC_0012622 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 15.2 | 71 | female | 0 | 10 | 2.6 | 5 | entrectinib 600 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:36:00.053399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706223 | REC_0012623 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 6.9 | 80 | male | 2 | 13 | 4.8 | 2 | osimertinib 80 mg daily | 23.6 | false | MSS | 2026-03-15T05:36:00.053822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373718 | REC_0012624 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 15.1 | 68 | male | 0 | 18 | 2.4 | 5 | sotorasib 960 mg daily | 5.9 | true | MSI-H | 2026-03-15T05:36:00.054461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366158 | REC_0012625 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 15 | 10.3 | 80 | female | 1 | 15 | 7.3 | 7 | pembrolizumab 200 mg q3w | 14.2 | true | MSS | 2026-03-15T05:36:00.054901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439325 | REC_0012626 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 16.1 | 76 | female | 2 | 19 | 5.3 | 6 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:00.055246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367139 | REC_0012627 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 18.4 | 77 | female | 2 | 17 | 6.9 | 6 | sotorasib 960 mg daily | 14 | false | MSS | 2026-03-15T05:36:00.055611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352369 | REC_0012628 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 37 | 4.4 | 90 | female | 1 | 53 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:36:00.055957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928673 | REC_0012629 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 8.9 | 71 | female | 1 | 16 | 6 | 1 | pembrolizumab 200 mg q3w | 18.8 | false | MSS | 2026-03-15T05:36:00.056497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639173 | REC_0012630 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 5.8 | 59 | male | 0 | 15 | 7.6 | 2 | osimertinib 80 mg daily | 23.3 | true | MSS | 2026-03-15T05:36:00.056913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467301 | REC_0012631 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.5 | 54 | female | 0 | 12 | 6.9 | 7 | sotorasib 960 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:36:00.057304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740086 | REC_0012632 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.5 | 75 | female | 2 | 27 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:36:00.057800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361959 | REC_0012633 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.3 | 67 | male | 0 | 30 | 6.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.2 | false | MSS | 2026-03-15T05:36:00.058168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320416 | REC_0012634 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 15 | 65 | male | 0 | 17 | 5 | 1 | sotorasib 960 mg daily | 22.6 | false | MSI-H | 2026-03-15T05:36:00.058499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338626 | REC_0012635 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.8 | 68 | female | 1 | 20 | 5.2 | 7 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:00.058847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806072 | REC_0012636 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 15.7 | 65 | female | 0 | 6 | 6.2 | 2 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:36:00.059229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649823 | REC_0012637 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 5.5 | 67 | female | 0 | 17 | 5.1 | 5 | pembrolizumab 200 mg q3w | 16.9 | false | MSS | 2026-03-15T05:36:00.059761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526179 | REC_0012638 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 15.8 | 66 | female | 1 | 24 | 5.3 | 2 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:36:00.060203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247581 | REC_0012639 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 4 | 61 | female | 1 | 14 | 5.3 | 3 | pembrolizumab 200 mg q3w | 13.6 | false | MSS | 2026-03-15T05:36:00.060589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930070 | REC_0012640 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.5 | 85 | female | 2 | 19 | 5.4 | 5 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:36:00.061001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168859 | REC_0012641 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.4 | 72 | female | 1 | 51 | 7.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:36:00.061369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795165 | REC_0012642 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 8.1 | 69 | female | 1 | 23 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 21 | false | MSS | 2026-03-15T05:36:00.061718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534381 | REC_0012643 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 7.4 | 60 | female | 0 | 20 | 6.5 | 7 | pembrolizumab 200 mg q3w | 7.9 | true | MSS | 2026-03-15T05:36:00.062029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564438 | REC_0012644 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8.9 | 83 | male | 1 | 19 | 5.1 | 5 | alectinib 600 mg BID | 9.2 | true | MSS | 2026-03-15T05:36:00.062328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282314 | REC_0012645 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.9 | 65 | male | 0 | 17 | 5.1 | 7 | entrectinib 600 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:00.062647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139987 | REC_0012646 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.5 | 69 | female | 0 | 40 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:36:00.063012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456821 | REC_0012647 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 13.8 | 74 | female | 2 | 26 | 5.5 | 1 | osimertinib 80 mg daily | 19.2 | false | MSI-H | 2026-03-15T05:36:00.063374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181559 | REC_0012648 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 17.5 | 56 | male | 1 | 15 | 5.2 | 4 | osimertinib 80 mg daily | 15.8 | false | MSI-H | 2026-03-15T05:36:00.063705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335907 | REC_0012649 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.7 | 74 | female | 2 | 2 | 6.7 | 1 | sotorasib 960 mg daily | 15.9 | false | MSS | 2026-03-15T05:36:00.063997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658999 | REC_0012650 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 9 | 74 | female | 1 | 0 | 6.5 | 0 | entrectinib 600 mg daily | 18.8 | false | MSS | 2026-03-15T05:36:00.064554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204128 | REC_0012651 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 12.4 | 66 | female | 0 | 21 | 6.3 | 1 | pembrolizumab 200 mg q3w | 16.9 | false | MSI-H | 2026-03-15T05:36:00.064932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557118 | REC_0012652 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.8 | 81 | female | 1 | 17 | 6.7 | 5 | alectinib 600 mg BID | 13.1 | true | MSS | 2026-03-15T05:36:00.065266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860677 | REC_0012653 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 17.9 | 74 | female | 1 | 17 | 2.3 | 1 | alectinib 600 mg BID | 27.2 | false | MSS | 2026-03-15T05:36:00.065595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883226 | REC_0012654 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 13.9 | 72 | female | 3 | 16 | 4.6 | 5 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:00.065962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749821 | REC_0012655 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.7 | 64 | female | 0 | 13 | 4.8 | 4 | entrectinib 600 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:36:00.066331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831649 | REC_0012656 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.5 | 67 | female | 1 | 23 | 6 | 3 | entrectinib 600 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:00.066630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239735 | REC_0012657 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.6 | 75 | female | 0 | 19 | 4.5 | 4 | entrectinib 600 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:36:00.066925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530352 | REC_0012658 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 9.2 | 78 | female | 2 | 7 | 6.2 | 4 | osimertinib 80 mg daily | 18.8 | false | MSS | 2026-03-15T05:36:00.067251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835402 | REC_0012659 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 30 | 8.1 | 71 | male | 1 | 20 | 4.4 | 0 | osimertinib 80 mg daily | 51.3 | false | MSS | 2026-03-15T05:36:00.067580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925559 | REC_0012660 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 8.8 | 48 | male | 0 | 14 | 4.8 | 2 | osimertinib 80 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:00.067922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686908 | REC_0012661 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.3 | 70 | female | 1 | 14 | 6.1 | 4 | osimertinib 80 mg daily | 13.9 | true | MSS | 2026-03-15T05:36:00.068339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741369 | REC_0012662 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 15.4 | 51 | male | 0 | 16 | 5.5 | 1 | osimertinib 80 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:36:00.068728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412783 | REC_0012663 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.6 | 73 | female | 1 | 31 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.8 | false | MSS | 2026-03-15T05:36:00.069349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581605 | REC_0012664 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 11 | 71 | female | 2 | 7 | 5.8 | 2 | alectinib 600 mg BID | 16 | false | MSI-H | 2026-03-15T05:36:00.069749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240229 | REC_0012665 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 12.9 | 50 | female | 0 | 11 | 5 | 2 | osimertinib 80 mg daily | 16 | false | MSS | 2026-03-15T05:36:00.070120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214825 | REC_0012666 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3 | 65 | male | 0 | 87 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:36:00.070534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479650 | REC_0012667 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 13.5 | 71 | female | 2 | 13 | 4.8 | 1 | osimertinib 80 mg daily | 15.3 | true | MSI-H | 2026-03-15T05:36:00.070922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961597 | REC_0012668 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 18.6 | 76 | female | 1 | 7 | 4.6 | 5 | sotorasib 960 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:36:00.071436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219719 | REC_0012669 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 16 | 12.5 | 74 | female | 1 | 17 | 4.8 | 0 | osimertinib 80 mg daily | 30 | true | MSS | 2026-03-15T05:36:00.071842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575565 | REC_0012670 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.8 | 68 | female | 1 | 39 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.7 | true | MSS | 2026-03-15T05:36:00.072264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575562 | REC_0012671 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.9 | 61 | male | 1 | 6 | 7.3 | 5 | osimertinib 80 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:36:00.072615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716902 | REC_0012672 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 7.6 | 69 | female | 0 | 11 | 4.7 | 2 | osimertinib 80 mg daily | 20.5 | false | MSS | 2026-03-15T05:36:00.072926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414242 | REC_0012673 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 7.7 | 63 | female | 1 | 15 | 4.6 | 1 | pembrolizumab 200 mg q3w | 22.1 | true | MSS | 2026-03-15T05:36:00.073242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921149 | REC_0012674 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.1 | 66 | female | 1 | 40 | 8.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.7 | true | MSS | 2026-03-15T05:36:00.073535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541767 | REC_0012675 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 5.8 | 63 | male | 1 | 8 | 5.1 | 7 | entrectinib 600 mg daily | 12.2 | true | MSS | 2026-03-15T05:36:00.073821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327847 | REC_0012676 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 6.2 | 77 | female | 2 | 11 | 4 | 2 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:36:00.074225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305760 | REC_0012677 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.7 | 62 | female | 1 | 21 | 5.4 | 1 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:00.074507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170807 | REC_0012678 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 25 | 8.4 | 58 | female | 0 | 52 | 7.2 | 0 | pembrolizumab 200 mg q3w | 47.8 | true | MSS | 2026-03-15T05:36:00.074752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405763 | REC_0012679 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 16.8 | 74 | female | 2 | 7 | 5.8 | 1 | sotorasib 960 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:00.075005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208647 | REC_0012680 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6 | 55 | female | 1 | 69 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:36:00.075249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671949 | REC_0012681 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 12.9 | 53 | female | 0 | 16 | 6.5 | 6 | sotorasib 960 mg daily | 11 | true | MSI-H | 2026-03-15T05:36:00.075521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407836 | REC_0012682 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 36 | 4.7 | 69 | female | 0 | 31 | 6.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.5 | true | MSS | 2026-03-15T05:36:00.075787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385071 | REC_0012683 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 15.5 | 76 | female | 2 | 6 | 4.3 | 4 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:36:00.076128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328181 | REC_0012684 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 19.4 | 67 | male | 0 | 21 | 7.6 | 5 | entrectinib 600 mg daily | 4.3 | true | MSI-H | 2026-03-15T05:36:00.076503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228821 | REC_0012685 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.9 | 73 | female | 2 | 18 | 2.8 | 6 | entrectinib 600 mg daily | 10 | false | MSI-H | 2026-03-15T05:36:00.076848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852968 | REC_0012686 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.5 | 66 | female | 1 | 14 | 6.3 | 6 | entrectinib 600 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:00.077180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173504 | REC_0012687 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 21.4 | 64 | male | 1 | 17 | 4.8 | 6 | entrectinib 600 mg daily | 15 | true | MSI-H | 2026-03-15T05:36:00.077493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602684 | REC_0012688 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 19.5 | 72 | female | 2 | 14 | 5.2 | 4 | entrectinib 600 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:36:00.077807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687606 | REC_0012689 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 11.7 | 71 | female | 0 | 12 | 3.5 | 2 | osimertinib 80 mg daily | 24.9 | false | MSS | 2026-03-15T05:36:00.078299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689404 | REC_0012690 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 16.9 | 70 | female | 1 | 17 | 6.1 | 8 | osimertinib 80 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:36:00.078696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878832 | REC_0012691 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 17.7 | 74 | female | 2 | 15 | 5.5 | 5 | osimertinib 80 mg daily | 12.7 | true | MSS | 2026-03-15T05:36:00.079085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766014 | REC_0012692 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.1 | 79 | female | 2 | 17 | 3.1 | 4 | entrectinib 600 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:36:00.079465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141858 | REC_0012693 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.2 | 62 | female | 1 | 91 | 7 | 5 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:36:00.079811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561281 | REC_0012694 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 12.9 | 75 | male | 1 | 23 | 4.9 | 2 | entrectinib 600 mg daily | 21 | true | MSI-H | 2026-03-15T05:36:00.080259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664709 | REC_0012695 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.5 | 72 | female | 1 | 10 | 5.8 | 6 | osimertinib 80 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:36:00.080693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573876 | REC_0012696 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 8.4 | 75 | female | 2 | 9 | 6.2 | 5 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:36:00.081050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218706 | REC_0012697 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.5 | 80 | female | 3 | 27 | 6 | 5 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:36:00.081391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674532 | REC_0012698 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 14.2 | 64 | female | 0 | 9 | 7.1 | 3 | entrectinib 600 mg daily | 18.3 | false | MSI-H | 2026-03-15T05:36:00.081722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603512 | REC_0012699 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 8.6 | 73 | female | 1 | 13 | 5.9 | 5 | pembrolizumab 200 mg q3w | 5.6 | true | MSS | 2026-03-15T05:36:00.082086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339802 | REC_0012700 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.2 | 72 | female | 2 | 26 | 4.5 | 8 | pembrolizumab 200 mg q3w | 5.7 | true | MSS | 2026-03-15T05:36:00.082477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.